Experts offer information and cancer centers take precautions in light of the novel coronavirus, and the Food and Drug Administration approves an immunotherapy combination for liver cancer.
The incidence of colorectal cancer – the fourth most common cancer diagnosed in the United States – has been steadily declining since the late 1990s. Despite this decrease, it is estimated that the lifetime risk of developing the disease is roughly one in 20 for those living in the United States. If the cancer is caught early when it is still localized, the five-year relative survival is almost 90 percent. However, if diagnosed after it has metastasized, the five-year relative survival is less than 15 percent.
A report shows that colorectal cancer incidence is decreasing in older adults while simultaneously rising in younger individuals, and more news of the week from Cancer Today.
Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.
Researchers find a possible explanation for the link between certain gut bacteria and colorectal cancer and other cancer news of the week from Cancer Today magazine staff.
Tracking health problems in young cancer survivors and other cancer news of the week from Cancer Today magazine staff.
Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and treatment are only recently being extensively explored. An emerging method known as liquid biopsy examines ctDNA, cell-free DNA (cfDNA), or circulating tumor cells in blood plasma samples to learn about the patient’s cancer without needing to resect tissue from the tumor itself, as is typically required in traditional diagnostic and staging methods. Liquid biopsy could, therefore, provide a minimally invasive technique to detect and characterize cancer and to monitor its response to treatment.
February is National Cancer Prevention Month. We recently had the opportunity of speaking with American Association for Cancer Research (AACR) Past President William Hait, MD, PhD, a leading expert in cancer prevention and interception. Hait, who is a Fellow of the AACR Academy and the current AACR treasurer, forecasted several key areas of advancement in this field. In this excerpt from our previous post, Hait shares his predictions for cancer prevention and interception research in 2020.
A study illuminates the alcohol consumption habits of cancer survivors.
Medical oncologist and lung cancer expert Roy S. Herbst, MD, PhD, discusses early data on drugs that target a mutated form of the KRAS protein
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More